Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NB-1008
- Development stage
- Phase 1
- Lead developer
- BlueWillow Biologics
- Modality
- Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intranasal
01
Overview
**NB-1008** is an investigational intranasal, nanoemulsion-adjuvanted seasonal influenza vaccine originally developed by NanoBio and continued by BlueWillow Biologics. It combines the licensed inactivated influenza vaccine Fluzone with the W805EC oil-in-water nanoemulsion adjuvant for nasal administration. The formulation is intended to induce influenza antigen-specific mucosal, systemic humoral, and T-helper-1-skewed cellular immune responses; it was evaluated in completed Phase 1 studies in healthy adults using nasal drops and a nasal sprayer. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01333462?viewType=Card))
- Other names
- Fluzone + 60% W805ECFluzone + W805ECinactivated nasal influenza vaccine NB-1008
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on NB-1008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NB-1008.